Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Common Equity: 2020-2025

Historic Common Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$9.2 million.

  • Insight Molecular Diagnostics' Common Equity fell 194.70% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.2 million, marking a year-over-year decrease of 194.70%. This contributed to the annual value of -$12.3 million for FY2024, which is 159.97% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Common Equity stood at -$9.2 million for Q3 2025, which was down 937.52% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Common Equity ranged from a high of $106.6 million in Q1 2021 and a low of -$12.3 million during Q4 2024.
  • For the 3-year period, Insight Molecular Diagnostics' Common Equity averaged around $13.5 million, with its median value being $10.9 million (2024).
  • Per our database at Business Quant, Insight Molecular Diagnostics' Common Equity surged by 191.13% in 2021 and then tumbled by 194.70% in 2025.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Common Equity stood at $65.2 million in 2021, then tumbled by 47.42% to $34.3 million in 2022, then plummeted by 40.31% to $20.5 million in 2023, then crashed by 159.97% to -$12.3 million in 2024, then plummeted by 194.70% to -$9.2 million in 2025.
  • Its Common Equity was -$9.2 million in Q3 2025, compared to $1.1 million in Q2 2025 and $10.2 million in Q1 2025.